SCHEMBL4871933

SCHEMBL4871933

CC(C)(C)OC(=O)N1CCC(/C=C/c2ccc3c(=O)[nH]cnc3c2)(c2ccc(Cl)cc2)CC1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.40
CNR1 P21554 3/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
ALOX15 P16050 1/20 0.36
KDR P35968 2/20 0.35
TEK Q02763 2/20 0.35
ADAM17 P78536 1/20 0.35
STS P08842 1/20 0.35
IDE P14735 1/20 0.35
TNKS O95271 2/20 0.34
PARP1 P09874 2/20 0.34
TNKS2 Q9H2K2 2/20 0.34
GPR119 Q8TDV5 1/20 0.34
GPR4 P46093 1/20 0.34
OPRD1 P41143 1/20 0.34
OPRK1 P41145 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4871940 1.00 ALDH1A1 (0.40) ALDH1A1CNR1MEN1KMT2AALOX15
SCHEMBL4873643 0.80 ALDH1A1 (0.41) ALDH1A1CNR1MEN1KMT2AKDR
SCHEMBL4876787 0.80 ALDH1A1 (0.50) ALDH1A1ALOX15KDRTEKPARP1
SCHEMBL4876792 0.80 ALDH1A1 (0.50) ALDH1A1ALOX15KDRTEKPARP1
Hydrochloric Acid SCHEMBL4869739 0.79 ALDH1A1 (0.49) ALDH1A1ALOX15KDRTEKPARP1
Hydrochloric Acid SCHEMBL4869731 0.79 ALDH1A1 (0.49) ALDH1A1ALOX15KDRTEKPARP1
SCHEMBL18130499 0.73 SLC2A1 (0.43) ADAM17PARP1OPRD1OPRK1
SCHEMBL1001982 0.72 MEN1 (0.53) MEN1KMT2AALOX15STS
SCHEMBL4878266 0.71 KMT2A (0.52) MEN1KMT2ASTS
SCHEMBL16596214 0.68 CHEK2 (0.51) GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080275029-A1 Compounds for Treating Protein-Kinase Mediated Disorders ASTEX THERAPEUTICS LIMITED (GB) 2008-11-06 US disclosed
US-20080275029-A1 Compounds for Treating Protein-Kinase Mediated Disorders ASTEX THERAPEUTICS LIMITED (GB) 2008-11-06 US disclosed
US-20080275029-A1 Compounds for Treating Protein-Kinase Mediated Disorders ASTEX THERAPEUTICS LIMITED (GB) 2008-11-06 US disclosed
EP-1814552-A2 COMPOUNDS FOR TREATING PROTEIN-KINASE MEDIATED DISORDERS Astex Therapeutics Limited (GB) 2007-08-08 EP disclosed
WO-2006051290-A2 COMPOUNDS FOR TREATING PROTEIN-KINASE MEDIATED DISORDERS ASTEX THERAPEUTICS LIMITED (GB) 2006-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275029-A1 Compounds for Treating Protein-Kinase Mediated Disorders CNKSR1, PRKCH, PRKAR2B ALDH1A1 4843/4885CNR1 470/4885MEN1 2004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.